As early as 2005, in multiple mouse tumor models, researchers discovered that simultaneously blocking the independent redundant pathways mediated by anti-CTLA-4 and anti-PD1 could induce and/or expand the repertoire of tumor-reactive T cell epitopes. This evidence concerns the gene CTLA4 and neoplasm.